Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T :

'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'

Related Keywords

San Diego , California , United States , New York , University Of Rochester , American , Morphosys Incyte , Mazyar Shadman , Jonathanw Friedberg , Bristol Myers Squibb , American Society Of Hematology , International Blood Marrow Transplant Research , Division Of Medical Oncology , Wilmot Cancer Institute , University Of Washington , Astrazeneca , Genentech , Medical Oncology , American Society , International Blood , Marrow Transplant Research , Samuel Durand Professor , Fate Therapeutics , Mustang Bio , Non Hodgkin Amp 039s Lymphoma , Non Hodgkin Lymphoma , Hl , Biologic Therapy , Iologics , Chimeric Antigen Receptort Cell Therapy , Chimeric Antigen Receptors , Himeric Immunoreceptors , Himerict Cell Receptors , Rtificialt Cell Receptors , Art Chimaeric Antigen Receptort Cell Therapy Receptors Immunoreceptors Chimaerict , Remission ,